DMTK - DermTech, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
13.19
-0.06 (-0.45%)
At close: 4:00PM EST
Stock chart is not supported by your current browser
Previous Close13.25
Open14.00
Bid0.00 x 1000
Ask0.00 x 900
Day's Range12.82 - 14.00
52 Week Range4.52 - 23.24
Volume56,576
Avg. Volume44,920
Market Cap158M
Beta (5Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)-3.34
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est15.00
  • Business Wire

    DermTech, Inc. Reports Third Quarter 2019 Financial Results and Provides Corporate Update

    DermTech, Inc. , a leader in precision dermatology enabled by a non-invasive skin genomics platform, today reported business and financial results as of and for the quarter ended September 30, 2019 and provided a corporate update.

  • Business Wire

    DermTech to Present at Upcoming Investor Conferences

    DermTech, Inc. , a leader in precision dermatology enabled by a non-invasive skin genomics platform, today announced that company manage

  • Business Wire

    DermTech Receives CPT® Proprietary Laboratory Assay Code from the American Medical Association

    This press release includes “forward-looking statements” within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995. The expectations, estimates, and projections of DermTech may differ from their actual results and consequently, you should not rely on these forward-looking statements as predictions of future events. Words such as “expect,” “estimate,” “project,” “budget,” “forecast,” “anticipate,” “intend,” “plan,” “may,” “will,” “could,” “should,” “believes,” “predicts,” “potential,” “continue,” and similar expressions are intended to identify such forward-looking statements.

  • Business Wire

    DermTech Presents New Data at Fall Clinical Dermatology Conference

    DermTech, Inc. , a leader in precision dermatology enabled by a non-invasive skin genomics platform, announced today the presentation of new data on the Pigmented Lesion Assay at the Fall Clinical Dermatology Conference in Las Vegas, NV.

  • Business Wire

    DermTech Announces Common Stock Will Continue Trading on The Nasdaq Capital Market; Warrant Delisting from The Nasdaq Capital Market

    DermTech, Inc. (NASDAQ: DMTK) (“DermTech” or the “Company”), a leader in precision dermatology enabled by a non-invasive skin genomics platform, announced today its common stock will continue trading on The Nasdaq Capital Market under the symbol “DMTK.” On October 16, 2019, the Nasdaq Hearings Panel (the “Panel”) notified DermTech that it has granted the Company’s request for continued listing of its common stock on The Nasdaq Capital Market because the Company meets all of the requirements for initial listing. The Panel also determined to delist the Company’s warrants previously trading on The Nasdaq Capital Market under the ticker symbol “DMTKW” (the “Public Warrants”) due to the Company’s failure to demonstrate compliance with Nasdaq Listing Rule 5515(a)(4), which requires the Company to have a minimum of 400 round lot holders of its publicly traded warrants.

  • Business Wire

    DermTech’s Test Included in Expert Panel’s Clinical Management Recommendations for Cutaneous Melanoma

    DermTech, Inc. (NASDAQ: DMTK) (“DermTech”), a global leader in precision dermatology enabled by a non-invasive skin genomics platform, announced today its inclusion in Clinical Management Recommendations, “Appropriate Use Criteria for the Integration of Diagnostic and Prognostic Gene Expression Profile Assays into the Management of Cutaneous Malignant Melanoma: An Expert Panel Consensus-Based Modified Process Assessment” published in the September issue of SKIN. A panel of dermatologists and dermatopathologists with expertise in pigmented lesions, melanoma, and gene expression technology evaluated commercially available gene expression tests to provide recommendations for use in specific clinical situations. The expert panel recommended use of the non-invasive PLA (Pigmented Lesion Assay), or 2-Gene Expression Profile test, in cases in which patients present with atypical lesions requiring additional assessment beyond visual inspection in order to inform the decision to surgically biopsy.

  • Business Wire

    DermTech Further Expands Patent Portfolio

    DermTech, Inc. , a global leader in precision dermatology enabled by a non-invasive skin genomics platform, announced today the issuance of patent, US 10,407,729, further expanding the company’s intellectual property and leadership position.